Premium
Myelofibrosis following treatment with a nitrosourea for malignant glioma
Author(s) -
McKenney Scott A.,
Fehir Kim M.
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19861001)58:7<1426::aid-cncr2820580708>3.0.co;2-s
Subject(s) - medicine , myelofibrosis , nitrosourea , bone marrow , radiation therapy , leukemia , oncology , glioma , chemotherapy , pathology , cancer research
Nitrosoureas are alkylating agents that have been associated with the development of a preleukemic syndrome, secondary acute nonlymphocytic leukemia and a variety of acute and delayed toxicities. Nitrosoureas have activity in the treatment of primary malignant brain tumors. The authors report a patient who developed bone marrow myelofibrosis three years following treatment with radiation therapy and oral CCNU. This is the first case of marrow fibrosis associated with the use of a nitrosourea. Bone marrow myelofibrosis may be another delayed treatment effect of this class of drugs.